ES2194895T3 - Peptidos natriureticas atriales especifico de un receptor. - Google Patents

Peptidos natriureticas atriales especifico de un receptor.

Info

Publication number
ES2194895T3
ES2194895T3 ES95901112T ES95901112T ES2194895T3 ES 2194895 T3 ES2194895 T3 ES 2194895T3 ES 95901112 T ES95901112 T ES 95901112T ES 95901112 T ES95901112 T ES 95901112T ES 2194895 T3 ES2194895 T3 ES 2194895T3
Authority
ES
Spain
Prior art keywords
human
receptor
receiver
natural peptides
special
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95901112T
Other languages
English (en)
Inventor
David Lowe
Brian C Cunningham
David Oare
Robert S Mcdowell
John Burnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2194895T3 publication Critical patent/ES2194895T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

LOS VARIANTES DEL FACTOR NATRIURETICO AURICULAR SELECTIVO DE RECEPTORES HUMANOS QUE CONTIENEN VARIOS SUSTITUYENTES, ESPECIALMENTE G16R, MUESTRAN UNA POTENCIA Y UNA AFINIDAD AL ENLACE IGUALES AL RECEPTOR A HUMANO PERO PRESENTAN UNA MENOR AFINIDAD AL ACLARAMIENTO O RECEPTOR C HUMANO. ESTOS VARIANTES DEL ANF TIENE UNA ACTIVIDAD NATRIURETICA, DIURETICA Y VASORRELAJANTE PERO PRESENTAN UNA MAYOR ESTABILIDAD METABOLICA, LO QUE LES HACE ADECUADOS PARA EL TRATAMIENTO DE COLAPSOS CONGESTIVOS, LESIONES RENALES AGUDAS Y DE LA HIPERTENSION RENAL.
ES95901112T 1993-11-12 1994-11-04 Peptidos natriureticas atriales especifico de un receptor. Expired - Lifetime ES2194895T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15299493A 1993-11-12 1993-11-12

Publications (1)

Publication Number Publication Date
ES2194895T3 true ES2194895T3 (es) 2003-12-01

Family

ID=22545344

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95901112T Expired - Lifetime ES2194895T3 (es) 1993-11-12 1994-11-04 Peptidos natriureticas atriales especifico de un receptor.

Country Status (10)

Country Link
EP (1) EP0728147B1 (es)
JP (1) JP3989535B2 (es)
AT (1) ATE232545T1 (es)
AU (1) AU1934995A (es)
CA (1) CA2174517C (es)
DE (1) DE69432123T2 (es)
DK (1) DK0728147T3 (es)
ES (1) ES2194895T3 (es)
PT (1) PT728147E (es)
WO (1) WO1995013296A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
EP0939770A1 (en) * 1996-10-22 1999-09-08 Genentech, Inc. Receptor specific brain natriuretic peptide (bnp)
AU6820898A (en) * 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
US6013630A (en) * 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
KR101434612B1 (ko) 2006-03-30 2014-08-26 팔라틴 테크놀로지스 인코포레이티드 사이클릭 나트륨 이뇨 펩타이드 구조물
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001940A1 (en) * 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
EP0465097A3 (en) * 1990-06-26 1993-03-24 Merck & Co. Inc. Peptides having atrial natriuretic factor activity

Also Published As

Publication number Publication date
JP3989535B2 (ja) 2007-10-10
EP0728147A1 (en) 1996-08-28
DE69432123T2 (de) 2004-01-08
CA2174517A1 (en) 1995-05-18
DK0728147T3 (da) 2003-06-10
JPH09505049A (ja) 1997-05-20
WO1995013296A1 (en) 1995-05-18
CA2174517C (en) 2007-01-02
ATE232545T1 (de) 2003-02-15
PT728147E (pt) 2003-06-30
EP0728147B1 (en) 2003-02-12
DE69432123D1 (de) 2003-03-20
AU1934995A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
ES2194895T3 (es) Peptidos natriureticas atriales especifico de un receptor.
ATE322871T1 (de) Niedrig- profil selbst-expandierbarer blutgefäss stent
CA2303344A1 (en) Improved stent configurations
FI952217A7 (fi) Verisuoniproteesi, johon on imeytetty hepariinia sisältävä kollageenitiiviste
FR2697525B1 (fr) Peptides de fusion ayant une activité de liaison à la streptavidine.
EP1439193A3 (en) Antibody directed to polypeptide having heparanase activity
EP0621683A3 (en) Dual mode radiotelephone terminal.
DE69113547D1 (de) Halbautomatische Druckgaswaffe.
TR199600246A2 (tr) Frenlemeli protez mafsal.
DE69830509D1 (de) Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration
EP0769554A3 (en) Human CNP gene and precursor protein
DE3670367D1 (de) Druckgasangetriebene munitionspatrone.
NO883731L (no) Isbrytende skip.
BG102817A (en) Modulators of factor traf asociated with tnf-receptor, their preparation and application
ES2104639T3 (es) Adnc para un peptido natriuretico de tipo c de rata, y proteina precursora.
ATE229542T1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
DE69840187D1 (de) Nahezu orthogonale Befehlsatz-Architektur für einen doppelten Multiplizierer-Akkumulierer mit einem Minimum von Kodierbits
EP0651099A3 (en) Connector for truss.
IL112557A0 (en) Peptides that are vip antagonists and pharmaceutical compositions comprising them
FR2684543B1 (fr) Ligament artificiel, notamment pour la cheville.
DE69808717D1 (de) Atriale natriuretische peptide (anp) als zusatzstoff für peritonealdialyse
EP0372503A3 (en) Anticoagulant peptides
FR2684291B1 (fr) Prothese de cheville.
EP0609292A4 (en) Soluble variants of type i membrane proteins, and methods of using them.
DE58903291D1 (de) Biocompatible dialysemembran aus einem gemischten polysaccharidester.